F Stock Chart Tue, Mar 4th, 2014

New Post Public Reply Private Reply Replies (0) Message Board
chartguy89
F Stock Chart and Technical Analysis - Tue, Mar 4th, 2014 $F

Period  Moving Average  Price Change  Percent Change  Average Volume
5 Day  11.84  +0.14  +1.20%  17,548,385
20 Day  11.52  +0.53  +4.72%  19,628,252
50 Day  11.17  +1.93  +19.63%  27,985,633
100 Day  10.18  +3.82  +48.11%  27,503,184
200 Day  9.15  +3.26  +38.35%  23,507,980
Year to Date  11.33  +1.13  +10.63%  30,157,754


Period  Raw Stochastic  Stochastic %K  Stochastic %D  Average True Range
9 Day 42.86% 44.26% 60.06% 0.31
14 Day 61.54% 59.35% 70.57% 0.33
20 Day 69.92% 65.91% 73.51% 0.33
50 Day 78.04% 77.03% 81.53% 0.29
100 Day 86.76% 86.02% 88.60% 0.25

Period  Relative Strength  Percent R  Historic Volatility  MACD Oscillator
9 Day 54.71% 57.14% 25.73% -0.08
14 Day 55.97% 38.46% 24.70% +0.04
20 Day 56.99% 30.08% 27.43% +0.19
50 Day 58.59% 21.96% 35.81% +0.54
100 Day 57.64% 13.24% 35.70% +1.52

F Stock Chart and Technical Analysis - Tue, Mar 4th, 2014
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Valour Inc. Unveils Advanced Leveraged ETPs for Crypto Trading

Updated Category News Views 86

Valour Inc. Launches Innovative Leveraged ETPs Valour Inc., a subsidiary of DeFi Technologies, is making waves in the financial technology sector by launching leveraged exchange-traded products (ETPs) focused on Bitcoin and Ethereum. These new offerings, titled Bull Bitcoin X2 Valour and Bull Ethereum X2 Valour, deliver twice the daily exposure to these leading...

Continue Reading
Inhibikase Therapeutics Makes Headway with $275 Million Financing

Updated Category News Views 84

Introduction to Inhibikase Therapeutics Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a pioneering clinical-stage pharmaceutical company dedicated to creating innovative therapeutics for cardiopulmonary and neurodegenerative diseases. Their commitment to developing high-quality treatments is evident in the recent announcement regarding an impressive financing deal....

Continue Reading
JBS USA Food Company's Successful Tender Offer for Notes

Updated Category News Views 341

Overview of the Tender Offer by JBS USA Food Company JBS USA Food Company recently shared exciting news about the successful conclusion of its cash tender offer for its 2.500% Senior Notes due 2027. The offer was designed for any and all outstanding notes, aimed at strengthening the company's financial position. Details on Tender Offer Results As reported, the results...

Continue Reading
Imaflex's Impressive Q2 2025 Results Show Resilience

Updated Category News Views 114

Strong Balance Sheet and Operational Agility Support Future Growth In a world where market dynamics can shift unexpectedly, Imaflex Inc. is finding ways to maintain robust performance despite the prevailing challenges. The company recently released its financial results for the second quarter of 2025 with notable highlights that showcase its resilience and strategic...

Continue Reading
A Decade of Growth: The Journey of Penumbra Stock Value

Updated Category News Views 158

Understanding Penumbra's Growth Over the Last Decade Penumbra (NYSE: PEN) has shown remarkable growth over the past decade, achieving an annualized return of 20.49%. This performance eclipses the market by an impressive 7.83% annually, making it a notable player in the healthcare sector. The Impact of Compounding Returns When it comes to investing, one fundamental...

Continue Reading